DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety Study of GB-0998 for Treatment of Steroid-Resistant Polymyositis and Dermatomyositis (PM/DM)

Information source: Mitsubishi Tanabe Pharma Corporation
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Polymyositis; Dermatomyositis

Intervention: GB-0998 (Drug); Placebo of GB-0998 (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Mitsubishi Tanabe Pharma Corporation

Official(s) and/or principal investigator(s):
Nobuyuki Miyasaka, Professor, Study Chair, Affiliation: Tokyo Medical and Dental University

Overall contact:
Clinical Trials Information Desk, Email: cti-inq-ml@ml.mt-pharma.co.jp

Summary

This randomized, double-blind, placebo-controlled trial will carry out to assess the efficacy of GB-0998 in the treatment of the steroid-resistant polymyositis and dermatomyositis based on the changes in manual muscle strength (MMT) scores as primary endpoint, and in addition, to assess the safety of GB-0998.

Clinical Details

Official title: A Randomized, Double-Blind, Controlled Clinical Study of GB-0998 for the Steroid-Resistant Polymyositis and Dermatomyositis

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Changes in manual muscle strength (MMT) scores

Secondary outcome:

Changes in the serum levels of creatine kinase (CK) and total scores of activities of daily living (ADL)

Adverse events and laboratory tests

Eligibility

Minimum age: 16 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients who have been defined as "definite" based on the criteria of Bohan and Peter

for polymyositis and dermatomyositis.

- Patients who are defined as steroid-resistant ones based on the changes of scores on

manual muscle testing (MMT) and serum levels of creatine kinase (CK) during observation period before administration of drug.

Exclusion Criteria:

- Patients with malignant tumors.

- Patients with acute interstitial pneumonia, including acute exacerbation of chronic.

- Patients with severe muscular atrophy for a long period.

- Patients with severe infectious disease.

- Patients who have the anamnesis of shock or hypersensitivity to this drug.

- Patients with severe hepatic disorder or severe renal disorder.

- Patients who have the anamnesis of cerebral infarction or ischemic heart disease, or

who having symptom of these diseases.

- Patients who have been diagnosed as IgA deficiency in their past history.

- Pregnant, lactating, and probably pregnant patients, and patients who want to become

pregnant.

- Patients who were administered immunoglobulin dosage within 6 weeks before consent.

Locations and Contacts

Clinical Trials Information Desk, Email: cti-inq-ml@ml.mt-pharma.co.jp

Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan; Recruiting
Hitoshi Kohsaka, Principal Investigator
Additional Information

Starting date: June 2006
Ending date: March 2009
Last updated: August 18, 2008

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012